KRAS and non-small cell lung carcinoma: For example, a CD73-targeted antibody–drug conjugate could remodel an immunosuppressive TME in multifaceted ways like diminishing levels of TAMs, MDSCs, and tumor vasculature, which inhibited the growth of tumors in KRAS-mutant NSCLC mice (69).